2 weeks Ago By ABMN Staff
Indaptus Therapeutics, Inc. ( NASDAQ:INDP – Get Free Report ) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 8,900 shares, a growth of 140.
5% from the August 31st total of 3,700 shares. Approximately 0.1% of the shares of the stock are sold short.
Based on an average daily volume of 12,200 shares, the short-interest ratio is presently 0.7 days. Wall Street Analyst Weigh In Separately, HC Wainwright reiterated a “buy” rating and set a $12.
00 target price on shares of Indaptus Therapeutics in a research report on Monday, June 17th. View Our Latest Stock Analysis on Indaptus Therapeutics Institutional Trading of Indaptus Therapeutics Indaptus Therapeutics Stock Up 22.6 % Shares of NASDAQ INDP opened at $1.
30 on Friday. Indaptus Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $3.
25. The business has a 50 day moving average price of $1.64 and a two-hundred day moving average price of $2.
08. The firm has a market cap of $11.10 million, a PE ratio of -0.
73 and a beta of 1.48. Indaptus Therapeutics ( NASDAQ:INDP – Get Free Report ) last announced its quarterly earnings results on Monday, August 12th.
The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.
07. On average, analysts anticipate that Indaptus Therapeutics will post -1.72 earnings per share for the current year.
Indaptus Therapeutics Company Profile ( Get Free Report ) Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. Featured Stories Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
